Vaccine Advisory Cmte. Will Expose Wide Audience To Uncertainties of Drug Development

Meetings have long been touted as a tool to boost public confidence in COVID vaccines, but those looking for clean-cut answers may be unsettled to learn about the unknowns that come with all drug development, particularly that done at speed. Advisors are there to offer an ‘unvarnished’ view, committee member Paul Offit says in an interview with the Pink Sheet in advance of the the VBRAC’s 22 October meeting.

Source: courtesy of Paul Offit

Paul Offit will serve on FDA's VBRAC, making recommendations on COVID-19 vaccine approvals.